RemeGen (HKG:9995) said China's drug regulator approved its Disitamab Vedotin for the treatment of a type of bladder cancer, according to a Hong Kong bourse filing Friday.
Shares of the firm gained over 4% in morning trade Monday.
The drug was approved in combination with toripalimab for the treatment of urothelial carcinoma which expresses the HER2 protein.
The approval marks the fifth indication for Disitamab Vedotin in China.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.